RecruitingPhase 1NCT05711615
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Studying Dedifferentiated liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Candace L Haddox, M.DDana-Farber - Harvard Cancer Center LAO
- Intervention
- Biopsy Procedure(procedure)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (16)
- Los Angeles General Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
- University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Siteman Cancer Center-South County, St Louis, Missouri, United States
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
- M D Anderson Cancer Center, Houston, Texas, United States
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05711615 on ClinicalTrials.govOther trials for Dedifferentiated liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06498648Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06422806Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06389799A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)Lund University Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05694871Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated LiposarcomaAlliance for Clinical Trials in Oncology
- ACTIVE NOT RECRUITINGPHASE2NCT05886634A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated LiposarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT05607095A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated LiposarcomaMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE3NCT04967521SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated LiposarcomaSarcoma Alliance for Research through Collaboration
- ACTIVE NOT RECRUITINGPHASE1NCT04420975Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaJonsson Comprehensive Cancer Center